Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Toxicology 2002-Jan

Increased T-lymphocyte dependent antibody production in female SJL/J mice following exposure to commercial grade malathion.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
Victor J Johnson
Alan M Rosenberg
Kwang Lee
Barry R Blakley

Märksõnad

Abstraktne

The organophosphate pesticide, malathion, was evaluated for effects on immune function in female SJL/J mice. Commercial grade malathion was dissolved in corn oil and administered at doses of 0.018-180 mg/kg to mice via oral gavage on alternate days for 28 days. Exposure to malathion did not alter brain acetylcholinesterase activity, body weight gain, organ/body weight ratios or food and water consumption during the treatment period. Malathion enhanced the primary IgM antibody response to sheep red blood cells (SRBCs) by approximately 150% (P<0.02) at all doses tested when the response was expressed per 10(6) viable spleen cells and per spleen. B-lymphocyte blastogenesis induced by lipopolysaccharide (LPS, P=0.10) was not affected by malathion exposure. T-lymphocyte blastogenesis induced by concanavalin A (ConA, P=0.23) and phytohemagglutinin (PHA-P, P=0.24) also was unaffected by treatment with malathion. Malathion had no effect on splenic macrophage phagocytosis (P>0.11). These results indicate that repeated oral administration of commercial-grade malathion increased antibody production following immunization with a T-lymphocyte dependent antigen at doses as low as 0.018 mg/kg, which is below the human allowable daily intake (0.02 mg/kg). These changes occurred in the absence of B- or T-lymphocyte hyper responsiveness or alterations in macrophage phagocytosis. Immune system alterations at a sub-clinical level following exposure to a commercial formulation of malathion may have an important impact on human and animal health risk assessment. Therefore, further investigation into the mechanisms responsible for the increased antibody production is warranted.

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge